The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel β-lactam/β-lactamase
combination antibiotics. The antimicrobial spectrum of activity of these antibiotics includes …

Infections caused by resistant gram‐negative bacteria are becoming increasingly prevalent
and now constitute a serious threat to public health worldwide because they are difficult to …

Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Background Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-
tazobactam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa …

Ceftolozane is a novel cephalosporin currently being developed with the β-lactamase
inhibitor tazobactam for the treatment of complicated urinary tract infections (cUTIs) …

Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR)
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …

Purpose An understanding of the pharmacokinetic (PK) and pharmacodynamic (PD)
principles that determine response to antimicrobial therapy can provide the clinician with …

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent
one of the most common hospital-acquired infections, carrying a significant morbidity and …

Klebsiella pneumoniae is an opportunistic pathogen that commonly causes nosocomial
infections in the urinary tract, respiratory tract, lung, wound sites and blood in individuals …